文章：

适合移植的新诊断多发性骨髓瘤患者的总生存期：现代诱导方案对治疗结果的比较有效性分析

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome

原文发布日期：2018-12-11

DOI: 10.1038/s41408-018-0163-7

类型: Article

开放获取: 是

英文摘要：

Overall survival (OS) of multiple myeloma has improved remarkably over time, with the recent Intergroupe Francophone du Myelome (IFM) 2009 randomized trial reporting a 4-year OS rate of approximately 82% in patients receiving modern therapy. However, survival estimates from clinical trials may overestimate outcomes seen in clinical practice even with the adjustment for age and other key characteristics. The purpose of this study was to determine the OS of myeloma patients seen in routine clinical practice who resembled the cohort studied in the IFM 2009 trial. A second goal was to conduct a brief comparative effectiveness analysis of bortezomib, lenalidomide, dexamethasone, and other major induction regimens used during the study period. We studied all patients with myeloma 65 years of age and younger, seen at the Mayo Clinic between January 1, 2010 and August 31, 2015, who had a stem cell harvest performed within 12 months of initial diagnosis. Patients with baseline serum creatinine >2 mg/dL were excluded. Five hundred and eighteen patients were studied. The 4-year OS rate was 82.3%, comparable to results achieved in the contemporaneous IFM randomized trial. The 4-year OS rates for standard and high-risk myeloma were 86.3% and 68.2%, respectively.

摘要翻译： 

多发性骨髓瘤的总生存期随时间推移显著改善，近期法国骨髓瘤工作组（IFM）2009年随机试验报告显示，接受现代治疗的患者4年总生存率约为82%。然而，即使根据年龄和其他关键特征进行调整，临床试验的生存估计仍可能高估临床实践中的实际结局。本研究旨在确定常规临床实践中与IFM 2009试验队列相似的骨髓瘤患者的总生存期，第二个目标是对研究期间使用的硼替佐米、来那度胺、地塞米松及其他主要诱导方案进行简要的疗效比较分析。我们纳入了2010年1月1日至2015年8月31日期间在梅奥诊所就诊、年龄在65岁及以下、并在初诊后12个月内进行干细胞采集的所有骨髓瘤患者，排除了基线血清肌酐>2mg/dL的患者。共纳入518例患者进行分析。其4年总生存率达82.3%，与同期IFM随机试验结果相当。标准风险与高风险骨髓瘤患者的4年总生存率分别为86.3%和68.2%。

原文链接：

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome